IBO on NYSE

IMPACT BIOMEDICAL INC.

American pharmaceutical preparations company, incorporated in Nevada. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Rafael Holdings, Inc., Lyell Immunopharma, Inc. or AcelRx Pharmaceuticals (United States), or pick any stock.

TickerIBO on NYSE¹
IndustryPharmaceutical Preparations¹
HeadquartersWest Henrietta, New York¹
Incorporated inNV²
Business address275 Wiregrass Pkwy,, West Henrietta, Ny 14586²
Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company²

See how the biggest companies compare on our leaderboards

(i) Global BioLife, Inc. (“Global BioLife”), which was incorporated on April 14, 2017, (ii) Impact BioLife Science, Inc.³ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-13381.2%Operating margin⁴

-36993.8%Net margin⁴

-93.9%Return on equity⁴

Where the money goes

Where each dollar of revenue went, fiscal 2025

Selling, general and adminInterestIncome tax

Cost of revenue8¢$424.0K
Research and development7¢$340.0K
Selling, general and admin17¢$873.0K
Interest16¢$793.0K
Income tax51¢$2.6M

Out of $32.0K in revenue.⁴ The company lost money this year.

Financial statements

Revenue⁵⁴$32.0K in 2025−36% since 2022

Operating income⁵⁶⁴-$4.3M in 2025+26% since 2022

Net income⁵⁶⁴-$11.8M in 2025+63% since 2022

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁴

Period ending	2025-12-31	2024-12-31
Total revenue	$32.0K
Cost of revenue	$424.0K
Sales, general and administrative compensation (inclusive of stock-based compensation)	$873.0K	$718.0K
Sales and marketing	$24.0K	$633.0K
Professional Fees	$1.0M	$446.0K
Research and development	$340.0K	$278.0K
Depreciation and Amortization	$1.1M	$1.1M
Rent and utilities	$74.0K	$32.0K
Impairment of goodwill		$25.1M
Impairment of fixed assets		$263.0K
Loss on disposal of fixed assets	$12.0K
Other operating expenses	$417.0K	$171.0K
Total costs and expenses	$4.3M	$28.8M
Operating loss	-$4.3M	-$28.8M
Interest income	$13.0K	$13.0K
Change in fair value of note payable, related party	-$9.4M	$5.1M
Interest expense	-$793.0K	-$1.1M
Loss from operations before income taxes	-$14.4M	-$24.7M
Income tax benefit (expense)	$2.6M	-$33.0K
Net loss	-$11.9M	-$24.8M
Loss from operations attributed to noncontrolling interest	$32.0K	$62.0K
Net loss attributable to common stockholders	-$11.8M	-$24.7M
Basic	-$0.38	-$2.30
Diluted	-$0.38	-$2.30
Basic	31.6M shares	10.8M shares
Diluted	31.6M shares	10.8M shares

Total assets⁵⁶⁴$17.4M in 2025−63% since 2022

Total liabilities⁵⁶⁴$1.9M in 2025−87% since 2022

Shareholders’ equity⁵⁶⁴$12.6M in 2025−68% since 2021

Cash⁵⁶⁴$3.0K in 2025+50% since 2022

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.⁴

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$3.0K	$2.0M
Accounts receivable	$5.0K
Inventory	$63.0K
Current portion of notes receivable	$198.0K	$184.0K
Prepaid expenses and other current assets	$142.0K	$265.0K
Total current assets	$411.0K	$2.4M
Property, plant and equipment, net		$17.0K
Notes receivable		$17.0K
Other intangible assets, net	$17.0M	$17.8M
Total assets	$17.4M	$20.3M
Accounts payable	$347.0K	$314.0K
Accrued expenses	$194.0K	$194.0K
Due to related party	$621.0K	$399.0K
Note payable, related party		$8.9M
Total current liabilities	$1.2M	$9.8M
Deferred tax liability, net	$688.0K	$3.3M
Total liabilities	$1.9M	$13.1M
Preferred stock, $0.001 par value; 100,000,000 shares authorized, zero shares issued and outstanding (60,496,041 on December 31, 2024); Liquidation value $0.001 per share, zero aggregate. $60,496,041,000 on December 31, 2024).		$60.0K
Common stock, $0.001 par value; 4,000,000,000 shares authorized, 104,621,231 shares issued and outstanding (11,503,955 on December 31, 2024)	$105.0K	$11.0K
Additional paid-in capital	$62.0M	$41.9M
Accumulated deficit	-$49.5M	-$37.7M
Total stockholders equity of the Company	$12.6M	$4.3M
Non-controlling interest in subsidiaries	$2.9M	$3.0M
Total stockholders equity	$15.6M	$7.2M	$28.3M
Total liabilities and stockholders equity	$17.4M	$20.3M
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	100.0M shares	100.0M shares
Preferred stock, shares issued	0 shares	60.5M shares
Preferred stock, shares outstanding	0 shares	60.5M shares
Preferred stock, liquidation preference per share	$0	$0
Preferred stock, liquidation preference value	$0	$60.5B
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	4.0B shares	4.0B shares
Common stock, shares issued	104.6M shares	11.5M shares
Common stock, shares outstanding	104.6M shares	11.5M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$3.0K	$2.0M
Accounts receivable	$5.0K
Inventory	$63.0K
Current portion of notes receivable	$198.0K	$184.0K
Prepaid expenses and other current assets	$142.0K	$265.0K
Total current assets	$411.0K	$2.4M
Property, plant and equipment, net		$17.0K
Notes receivable		$17.0K
Other intangible assets, net	$17.0M	$17.8M
Total assets	$17.4M	$20.3M
Accounts payable	$347.0K	$314.0K
Accrued expenses	$194.0K	$194.0K
Due to related party	$621.0K	$399.0K
Note payable, related party		$8.9M
Total current liabilities	$1.2M	$9.8M
Deferred tax liability, net	$688.0K	$3.3M
Total liabilities	$1.9M	$13.1M
Preferred stock, $0.001 par value; 100,000,000 shares authorized, zero shares issued and outstanding (60,496,041 on December 31, 2024); Liquidation value $0.001 per share, zero aggregate. $60,496,041,000 on December 31, 2024).		$60.0K
Common stock, $0.001 par value; 4,000,000,000 shares authorized, 104,621,231 shares issued and outstanding (11,503,955 on December 31, 2024)	$105.0K	$11.0K
Additional paid-in capital	$62.0M	$41.9M
Accumulated deficit	-$49.5M	-$37.7M
Total stockholders equity of the Company	$12.6M	$4.3M
Non-controlling interest in subsidiaries	$2.9M	$3.0M
Total stockholders equity	$15.6M	$7.2M	$28.3M
Total liabilities and stockholders equity	$17.4M	$20.3M
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	100.0M shares	100.0M shares
Preferred stock, shares issued	0 shares	60.5M shares
Preferred stock, shares outstanding	0 shares	60.5M shares
Preferred stock, liquidation preference per share	$0	$0
Preferred stock, liquidation preference value	$0	$60.5B
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	4.0B shares	4.0B shares
Common stock, shares issued	104.6M shares	11.5M shares
Common stock, shares outstanding	104.6M shares	11.5M shares

Cash from operations⁵⁶⁴-$1.9M in 2025−16% since 2022

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁴

Period ending	2025-12-31	2024-12-31
Loss from continuing operations	-$11.9M	-$24.8M
Depreciation and amortization	$1.1M	$1.1M
Stock based compensation	$13.0K	$19.0K
Issuance of shares for professional services rendered	$190.0K
Accrued interest on notes payable	$793.0K	$1.1M
Change in deferred tax liability	-$2.6M	$33.0K
Change in fair value of note payable, related party	$9.4M	-$5.1M
Impairment of inventory	$419.0K
Loss on disposal of fixed assets	$12.0K
Impairment of fixed assets		$263.0K
Impairment of goodwill		$25.1M
Accounts receivable	-$1.0K	$128.0K
Inventory	$7.0K
Prepaid expenses and other current assets	$126.0K	-$265.0K
Accounts payable	$470.0K	-$436.0K
Accrued expenses	-$2.0K	-$35.0K
Net cash used operating activities	-$1.9M	-$2.9M
Payments received on notes receivable	$3.0K	$2.0K
Net cash provided by investing activities	$3.0K	$2.0K
Borrowings from related party	$184.0K
Payments to related party	-$293.0K
Borrowings of note payable, related party		$1.1M
Issuances of common stock, net of issuance costs		$3.7M
Net cash (used) provided by financing activities	-$109.0K	$4.8M
Net increase (decrease) in cash	-$2.0M	$2.0M

Compare IMPACT BIOMEDICAL INC. with another company

Leadership

Who has led IMPACT BIOMEDICAL INC., and when. Pick a name to see everywhere that person has worked.

2025

Chief executive officerFrank D. Heuszel Sep 16, 2024 to Dec 9, 2024¹⁰
PresidentFrank D. Heuszel Sep 16, 2024 to Sep 16, 2024¹⁰
Chief financial officerTodd D. Macko Sep 16, 2024 to now¹¹
Chief operating officerMark Suseck Sep 16, 2024 to Sep 16, 2024¹²

Board members and other officers (8)

Board memberFai Chan Apr 2, 2025 to now¹³
Board memberCastel Berisford Hibbert Sep 16, 2024 to Sep 16, 2024¹⁴
Board memberChristian Thomas Zimmerman Sep 16, 2024 to Sep 16, 2024¹⁵
Board memberDavid K. Keene Sep 16, 2024 to Sep 16, 2024¹⁶
Board memberElise Brownell Sep 16, 2024 to Sep 16, 2024¹⁷
Board memberFrank D. Heuszel Sep 16, 2024 to Dec 9, 2024¹⁰
Board memberJason Grady Sep 16, 2024 to now¹⁸
Board memberMelissa Kaye Sims Sep 16, 2024 to Sep 16, 2024¹⁹

Timeline

Sep 16, 2024New chief executive Frank D. Heuszel becomes CEO¹⁰

Filings

137 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 18 major events, 29 insider forms, 2 large holders, 75 other. The latest 20:

Oct 9, 20268-K EDGAR
Sep 24, 20264 EDGAR
Sep 17, 20268-K EDGAR
Sep 15, 20268-K EDGAR
Aug 7, 202610-Q EDGAR
May 12, 202610-Q EDGAR
Apr 29, 2026144 EDGAR
Apr 22, 2026S-8 POS EDGAR
Apr 6, 2026S-8 POS EDGAR
Mar 30, 20264 EDGAR
Mar 25, 20264 EDGAR
Mar 11, 202610-K EDGAR
Mar 4, 20268-K EDGAR
Jan 6, 20264 EDGAR
Dec 30, 2025DEF 14C EDGAR
Dec 11, 2025PRE 14C EDGAR
Nov 7, 202510-Q EDGAR
Nov 6, 20258-K EDGAR
Oct 27, 20258-K EDGAR
Sep 22, 2025DEF 14A EDGAR

The 137 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

32 open-market trades by officers, directors and large owners since October 2021: 7 buys and 25 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Sep 24, 2026	DSS, INC.10% owner	Sale	156	$7.06	$1.1K	Form 4
Sep 23, 2026	DSS, INC.10% owner	Sale	27	$6.95	$188	Form 4
Sep 22, 2026	DSS, INC.10% owner	Sale	723	$0.55	$398	Form 4
Mar 27, 2026	Macko Todd DChief Financial Officer	Sale	43,400	$0.56	$24.3K	Form 4
Mar 25, 2026	Macko Todd DChief Financial Officer	Sale	1,600	$0.60	$960	Form 4
Mar 23, 2026	Grady JasonDirector	Sale	50,000	$0.65	$32.5K	Form 4
May 27, 2025	DSS, INC.10% owner	Sale	45,400	$0.54	$24.5K	Form 4
May 27, 2025	DSS, INC.10% owner	Sale	45,400	$0.54	$24.5K	Form 4
May 22, 2025	DSS, INC.10% owner	Sale	115,600	$0.55	$63.6K	Form 4
May 22, 2025	DSS, INC.10% owner	Sale	115,600	$0.55	$63.6K	Form 4
Apr 4, 2025	DSS, INC.10% owner	Sale	890,800	$0.95	$846.3K	Form 4
Apr 4, 2025	Alset Inc.10% owner	Sale	180,000	$0.96	$172.8K	Form 4
Apr 3, 2025	Chan Heng Fai AmbroseDirector	Sale	351,555	$0.50	$175.8K	Form 4
Apr 3, 2025	Alset Inc.10% owner	Sale	624,917	$0.67	$417.1K	Form 4
Apr 2, 2025	Alset Inc.10% owner	Sale	884,776	$0.60	$531.4K	Form 4
Apr 1, 2025	Alset International Ltd10% owner	Sale	2,226,918	$1.17	$2.6M	Form 4
Mar 31, 2025	Alset International Ltd10% owner	Sale	300,000	$1.03	$309.0K	Form 4
Mar 27, 2025	DSS, INC.10% owner	Sale	47,681	$2.50	$119.2K	Form 4
Mar 26, 2025	DSS, INC.10% owner	Sale	58,139	$3.13	$182.2K	Form 4
Mar 21, 2025	DSS, INC.10% owner	Sale	499,800	$3.30	$1.6M	Form 4

All 32 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Fai ChanSCHEDULE 13D/A, 2 filings Apr 2, 2025 to Apr 4, 2025²⁰

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARIMPACT BIOMEDICAL INC. filings on SEC EDGAR
2
SEC EDGARIMPACT BIOMEDICAL INC. filings on SEC EDGAR
3
SEC EDGARIMPACT BIOMEDICAL INC. annual report, Item 1 (Business)
4
SEC EDGARIMPACT BIOMEDICAL INC. 10-K for fiscal 2025
5
SEC EDGARIMPACT BIOMEDICAL INC. 10-K for fiscal 2022
6
SEC EDGARIMPACT BIOMEDICAL INC. 10-K for fiscal 2023
7
SEC EDGARIMPACT BIOMEDICAL INC. 10-Q for fiscal 2025
8
SEC EDGARIMPACT BIOMEDICAL INC. 10-Q for fiscal 2026
9
SEC EDGARIMPACT BIOMEDICAL INC. 10-Q for fiscal 2026
10
SEC EDGARFrank D. Heuszel, Chief executive officer
11
SEC EDGARTodd D. Macko, Chief financial officer
12
SEC EDGARMark Suseck, Chief operating officer
13
SEC EDGARFai Chan, Board member
14
SEC EDGARCastel Berisford Hibbert, Board member
15
SEC EDGARChristian Thomas Zimmerman, Board member
16
SEC EDGARDavid K. Keene, Board member
17
SEC EDGARElise Brownell, Board member
18
SEC EDGARJason Grady, Board member
19
SEC EDGARMelissa Kaye Sims, Board member
20
SEC EDGARFai Chan SCHEDULE 13D/A on IMPACT BIOMEDICAL INC.